These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 30324820)

  • 1. The safety of apatinib for the treatment of gastric cancer.
    Geng R; Song L; Li J; Zhao L
    Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
    Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
    Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Xu J; Liu X; Yang S; Shi Y
    Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
    Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
    Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
    Guo Y; Tang J; Huang XE; Cao J
    Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
    Xia X; Jiang W; Qi W; Hong B; Zhao W
    Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib for the treatment of gastric cancer.
    Geng R; Li J
    Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
    Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
    Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
    Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer.
    Yang Y; Wu X; Li F; Wang N; Zhang M; Sun T; Chen Z
    J Cancer Res Ther; 2019; 15(2):365-369. PubMed ID: 30964112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
    Scott LJ
    Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
    Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
    BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.
    Wang Y; Bi M; Zhang H; Gao Z; Zhou H; Chang S
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e528-e530. PubMed ID: 28028915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
    Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
    Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
    Liu X; Xu J; Li F; Liao Z; Ren Z; Zhu L; Shi Y; Zhao G; Bai X; Zhao J; Xing R; Teng S; Yang Y; Yang J
    Biomed Pharmacother; 2020 Feb; 122():109587. PubMed ID: 31786466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
    Du Y; Cao Q; Jiang C; Liang H; Ning Z; Ji C; Wang J; Zhou C; Jiang Z; Yu C; Li L; Zhao Y; Xu Y; Xu T; Hu W; Wang D; Cheng H; Wang G; Zhou J; Wang S; Zhang Y; Hu Z; Li X; Lu D; Zhang J; Xie H; Sun G
    Cancer Med; 2020 Jul; 9(14):5008-5014. PubMed ID: 32441892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma.
    Zeng DX; Lei W; Wang CG; Huang JA; Jiang JH
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):439-442. PubMed ID: 30547193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.